|
1
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: the impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li W, Ma Q, Liu J, et al: Hyperglycemia as
a mechanism of pancreatic cancer metastasis. Front Biosci.
17:1761–1774. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Garrido-Laguna I, Uson M, Rajeshkumar NV,
et al: Tumor engraftment in nude mice and enrichment in
stroma-related gene pathways predict poor survival and resistance
to gemcitabine in patients with pancreatic cancer. Clin Cancer Res.
17:5793–5800. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Saiki Y, Yoshino Y, Fujimura H, et al: DCK
is frequently inactivated in acquired gemcitabine-resistant human
cancer cells. Biochem Biophys Res Commun. 421:98–104. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
de Wolf C, Jansen R, Yamaguchi H, et al:
Contribution of the drug transporter ABCG2 (breast cancer
resistance protein) to resistance against anticancer nucleosides.
Mol Cancer Ther. 7:3092–3102. 2008.PubMed/NCBI
|
|
7
|
Schniewind B, Christgen M, Kurdow R, et
al: Resistance of pancreatic cancer to gemcitabine treatment is
dependent on mitochondria-mediated apoptosis. Int J Cancer.
109:182–188. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kagawa S, Takano S, Yoshitomi H, et al:
Akt/mTOR signaling pathway is crucial for gemcitabine resistance
induced by Annexin II in pancreatic cancer cells. J Surg Res.
178:758–767. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu H, Buchan RJ and Cook SA: MicroRNA-223
regulates Glut4 expression and cardiomyocyte glucose metabolism.
Cardiovasc Res. 86:410–420. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma F, Liu X, Li D, et al: MicroRNA-466l
upregulates IL-10 expression in TLR-triggered macrophages by
antagonizing RNA-binding protein tristetraprolin-mediated IL-10
mRNA degradation. J Immunol. 184:6053–6059. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ambros V: MicroRNA pathways in flies and
worms: growth, death, fat, stress, and timing. Cell. 113:673–676.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hummel R, Hussey DJ and Haier J:
MicroRNAs: predictors and modifiers of chemo- and radiotherapy in
different tumour types. Eur J Cancer. 46:298–311. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lima RT, Busacca S, Almeida GM, Gaudino G,
Fennell DA and Vasconcelos MH: MicroRNA regulation of core
apoptosis pathways in cancer. Eur J Cancer. 47:163–174. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schoof CR, Botelho EL, Izzotti A and dos
Vasques LR: MicroRNAs in cancer treatment and prognosis. Am J
Cancer Res. 2:414–433. 2012.PubMed/NCBI
|
|
15
|
Ratert N, Meyer HA, Jung M, et al:
Reference miRNAs for miRNAome analysis of urothelial carcinomas.
PLoS One. 7:e393092012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pallante P, Visone R, Ferracin M, et al:
MicroRNA deregulation in human thyroid papillary carcinomas. Endocr
Relat Cancer. 13:497–508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zanette DL, Rivadavia F, Molfetta GA, et
al: miRNA expression profiles in chronic lymphocytic and acute
lymphocytic leukemia. Braz J Med Biol Res. 40:1435–1440. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Visone R, Veronese A, Rassenti LZ, et al:
miR-181b is a biomarker of disease progression in chronic
lymphocytic leukemia. Blood. 118:3072–3079. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xi Y, Formentini A, Chien M, et al:
Prognostic values of microRNAs in colorectal cancer. Biomark
Insights. 2:113–121. 2006.PubMed/NCBI
|
|
20
|
Yan LX, Huang XF, Shao Q, et al: MicroRNA
miR-21 overexpression in human breast cancer is associated with
advanced clinical stage, lymph node metastasis and patient poor
prognosis. RNA. 14:2348–2360. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schaefer A, Jung M, Mollenkopf HJ, et al:
Diagnostic and prognostic implications of microRNA profiling in
prostate carcinoma. Int J Cancer. 126:1166–1176. 2010.PubMed/NCBI
|
|
22
|
Xu X, Jia R, Zhou Y, et al:
Microarray-based analysis: Identification of hypoxia-regulated
microRNAs in retinoblastoma cells. Int J Oncol. 38:1385–1393.
2011.PubMed/NCBI
|
|
23
|
Panarelli NC, Chen YT, Zhou XK,
Kitabayashi N and Yantiss RK: MicroRNA expression aids the
preoperative diagnosis of pancreatic ductal adenocarcinoma.
Pancreas. 41:685–690. 2012.PubMed/NCBI
|
|
24
|
Ciafre SA, Galardi S, Mangiola A, et al:
Extensive modulation of a set of microRNAs in primary glioblastoma.
Biochem Biophys Res Commun. 334:1351–1358. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen L, Yang Q, Kong WQ, et al:
MicroRNA-181b targets cAMP responsive element binding protein 1 in
gastric adenocarcinomas. IUBMB Life. 64:628–635. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dan Xia Z, Wei Z, Cheng F, et al:
miR-181a/b significantly enhances drug sensitivity in chronic
lymphocytic leukemia cells via targeting multiple anti-apoptosis
genes. Carcinogenesis. 33:1294–1301. 2012.PubMed/NCBI
|
|
27
|
Careccia S, Mainardi S, Pelosi A, et al: A
restricted signature of miRNAs distinguishes APL blasts from normal
promyelocytes. Oncogene. 28:4034–4040. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang B, Hsu SH, Majumder S, et al:
TGFbeta-mediated upregulation of hepatic miR-181b promotes
hepatocarcinogenesis by targeting TIMP3. Oncogene. 29:1787–1797.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakajima G, Hayashi K, Xi Y, et al:
Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are associated
with chemoresponse to S-1 in colon cancer. Cancer Genomics
Proteomics. 3:317–324. 2006.PubMed/NCBI
|
|
30
|
Lu Y, Roy S, Nuovo G, et al:
Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of
tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein
and modulating mitogenic signal. J Biol Chem. 286:42292–42302.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu W, Shan X, Wang T, Shu Y and Liu P:
miR-181b modulates multidrug resistance by targeting BCL2 in human
cancer cell lines. Int J Cancer. 127:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
An Y, Yao J, Wei JS, et al: Establish a
gemcitabine-resistant pancreatic cancer cell line SW1990/GZ and
research the relationship between SW1990/GZ and pancreatic cancer
stem cell. Zhonghua Wai Ke Za Zhi. 48:999–1003. 2010.(In
Chinese).
|
|
33
|
Friess H, Langrehr JM, Oettle H, et al: A
randomized multi-center phase II trial of the angiogenesis
inhibitor Cilengitide (EMD 121974) and gemcitabine compared with
gemcitabine alone in advanced unresectable pancreatic cancer. BMC
Cancer. 6:2852006. View Article : Google Scholar
|
|
34
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
|
|
35
|
Osman A: MicroRNAs in health and disease -
basic science and clinical applications. Clin Lab. 58:393–402.
2012.PubMed/NCBI
|
|
36
|
Fillat C and Altafaj X: Gene therapy for
Down syndrome. Prog Brain Res. 197:237–247. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ren Y, Gao J, Liu JQ, et al: Differential
signature of fecal microRNAs in patients with pancreatic cancer.
Mol Med Rep. 6:201–209. 2012.PubMed/NCBI
|
|
38
|
Liu J, Gao J, Du Y, et al: Combination of
plasma microRNAs with serum CA19-9 for early detection of
pancreatic cancer. Int J Cancer. 131:683–691. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hung SW, Mody HR and Govindarajan R:
Overcoming nucleoside analog chemoresistance of pancreatic cancer:
a therapeutic challenge. Cancer Lett. 320:138–149. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cory S and Adams JM: The Bcl2 family:
regulators of the cellular life-or-death switch. Nat Rev Cancer.
2:647–656. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
De Botton S, Sabri S, Daugas E, et al:
Platelet formation is the consequence of caspase activation within
megakaryocytes. Blood. 100:1310–1317. 2002.PubMed/NCBI
|
|
42
|
Zhao Y, Shen S, Guo J, et al:
Mitogen-activated protein kinases and chemoresistance in pancreatic
cancer cells. J Surg Res. 136:325–335. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dong J, Zhao YP, Zhou L, Zhang TP and Chen
G: Bcl-2 upregulation induced by miR-21 via a direct interaction is
associated with apoptosis and chemoresistance in MIA PaCa-2
pancreatic cancer cells. Arch Med Res. 42:8–14. 2011. View Article : Google Scholar
|
